EPFL INNOVATION PARK, BUILDING B, 1015 LAUSANNE, V8
Extraordinary General Meeting Proxy Card
Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764
Receives FDA Fast Track Designation for Anti-Alpha-synuclein Active Immunotherapy, ACI-7104, to Treat Early Parkinson’s Disease (PD)
Béatrice EHLERS NOTAIRE STATUTS
NASDAQ: ACIU | Annual General Meeting – June 11, 2026 Pioneering Precision Prevention Targeted Therapeutics for Neurodegenerative Diseases
To Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson’s Disease
Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload